Relief Therapeutics Holding AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Relief Therapeutics Holding AG
Coronavirus Notebook: EU & Australia Assessing Comirnaty In 5-11 Year Olds, Aviptadil Shows Promise In Critical COVID-19 Patients
The European Medicines Agency has OKd new manufacturing sites and a ready-to-use formulation for Comirnaty, while Australia has provisionally approved Ronapreve for treatment and post-exposure prophylaxis. The UK has secured supplies of two investigational antiviral products from Pfizer and MSD.
The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.
Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
- Large Molecule
- Other Names / Subsidiaries
- APR Applied Pharma Research SA
- THERAMetrics Holding AG